Table 1 Characteristics of AVM patients enrolled in a pilot clinical study to test effects of oral doxycycline treatment on MMP-9 in AVM lesions.
From: Suppression of MMP-9 by doxycycline in brain arteriovenous malformations
Group | Age | Gender | S-M score* | AVM size** | Draining veins | History of hemorrhage | Number of embolization treatments |
|---|---|---|---|---|---|---|---|
Dox | 50 | M | 4 | 38 | Superficial & Deep | No | 1 |
Dox | 48 | F | 4 | 30 | Deep | Yes | 0 |
Dox | 52 | M | 4 | 42 | Superficial & Deep | Yes | 2 |
Dox | 43 | M | 3 | 29 | Superficial & Deep | No | 1 |
Dox | 23 | M | 4 | 34 | Superficial & Deep | No | 2 |
Dox | 28 | M | 4 | 40 | Superficial | Yes | 2 |
Dox | 56 | M | 2 | 10 | Superficial | No | |
Dox | 41 | F | 3 | 30 | Superficial | No | 1 |
Dox | 62 | M | 2 | 41 | Superficial | No | 1 |
Dox | 42 | M | 2 | 2 | Superficial | Yes | 0 |
Placebo | 53 | M | 2 | 28 | Superficial & Deep | No | 1 |
Placebo | 17 | M | 1 | 18 | Superficial | No | 1 |
Placebo | 48 | F | 2 | 13 | Deep | No | 0 |
Placebo | 22 | M | 3 | 19 | Deep | Yes | 0 |